CytokineHumansMaleFemaleChemoradiotherapyMiddle Aged
Clinical observation of anti-PD-1/PD-L1 immunotherapy plus concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Xudong Sun, Dongmei Wu, Guangcheng Ding, Xueying Zhang, Changli Shi, Yulong Tian
Published: 202610.1016/j.cyto.2025.157096
Abstract
OBJECTIVE: This study analyzed the efficacy of the PD-1 inhibitor Sintilimab combined with concurrent chemoradiotherapy (CCRT) in patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: A retrospective study in…
Preview only. Read the full abstract at the source